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 Patient: Female, 28
 Final Diagnosis: Relapse of atypical hemolytic uremic syndrome during pregnancy
 Symptoms: Anemia • edema • hemolysis • oliguria
 Medication: —
 Clinical Procedure: —
 Specialty: Nephrology
 Objective: Rare disease
 Background: Atypical hemolytic uremic syndrome (aHUS) is a genetic disorder with uncontrolled complement activation 
leading to systemic thrombotic microangiopathy; kidneys are almost invariably involved. Eculizumab has dra-
matically improved the prognosis of aHUS and affected women in the childbearing age are more likely to con-
sider pregnancy, even if this could represent a risk for disease reactivation. Pregnancies in women with aHUS 
during Eculizumab treatment have been reported, with no cases of aHUS relapse.
 Case Report: We report the case of a female patient affected by aHUS with no specific gene mutations who had a pregnancy-
associated aHUS relapse at 26-weeks of gestation during maintenance Eculizumab treatment. The patient de-
veloped stage II acute kidney injury and microangiopathic hemolytic anemia. Delivery by cesarean section at 
week 27, plasma exchange sessions and several supplemental Eculizumab administrations were required. After 
appropriate treatment, the patient partially recovered kidney function; the baby had a prolonged stay in the 
intensive care unit and showed no signs of neurologic damage.
 Conclusions: Previous reports indicated that pregnancy-related aHUS relapses were unlikely in women undergoing Eculizumab 
treatment. Based on our case, we suggest caution in counselling pregnancy in women with aHUS treated with 
Eculizumab, especially in the absence of pathogenic mutations in complement-regulating genes. Clinicians 
should be aware of possible aHUS relapse in pregnancy during Eculizumab treatment.
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 Abbreviations: aHUS – atypical hemolytic uremic syndrome; TMA – thrombotic microangiopathy; PEX – plasma ex-
change; PNH – paroxysmal nocturnal hemoglobinuria; LDH – lactate dehydrogenase; CFH – comple-
ment factor H; MCP – membrane cofactor protein; CFI – complement factor I; CFB – complement factor B; 
THBD – thrombomodulin; CKD – chronic kidney disease; AKI – acute kidney injury
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Background
Atypical hemolytic uremic syndrome (aHUS) is a genetic dis-
order caused by defects in regulation of the complement 
cascade [1]. Uncontrolled activation of the complement sys-
tem leads to systemic thrombotic microangiopathy (TMA) [2]. 
Endothelial damage typically affects renal microvasculature; 
nevertheless, other organs can also be involved [3]. Atypical 
hemolytic uremic syndrome can occur at any age. Prognosis 
prior to currently available treatments have been reported to 
be poor with more than 50% of patients dying or reaching end 
stage renal disease within 3 to 5 years from onset [4].
Plasma exchange (PEX) or infusion has long been considered 
the gold standard treatment for aHUS [3]. Starting from 2009, 
Eculizumab, a recombinant humanized monoclonal antibody 
which binds with high affinity to C5 blocking the generation 
of pro-inflammatory C5a and C5b-9, has been used in patients 
with aHUS [5]. Eculizumab inhibits complement-mediated TMA 
and has been associated with significant time-dependent im-
provement in renal function in patients with aHUS [2].
Disease penetrance of aHUS is highly incomplete, and a patho-
genic mutation can be identified in only 40–60% of cases [6]. 
The clinical expression of the condition is commonly trig-
gered by infections and pregnancy [7]. Since pregnancy can 
be a cause of TMA reactivation, it has traditionally been dis-
couraged in women with aHUS [7,8]. However, the availabili-
ty of Eculizumab has dramatically improved the outcomes of 
aHUS, and affected women in the childbearing age are more 
likely to consider pregnancy.
Eculizumab has been used during pregnancy in women with 
paroxysmal nocturnal hemoglobinuria (PNH) [9]. Very scarce 
reports support its use in pregnancy in women with aHUS, and 
little is known about fetal and maternal outcomes.
Case Report
We report the case of a young Caucasian female diagnosed 
with aHUS at the age of 28 years. She had been previous-
ly healthy, and she had no family history for TMA. She ini-
tially presented to the emergency department with hemop-
tysis and arterial hypertension. Her laboratory examinations 
showed anemia (hemoglobin 9.2 g/dL), decreased platelet 
count (14 000/uL), increased lactate dehydrogenase (LDH) 
levels (3600 U/L), elevated serum creatinine (1.68 mg/dL), 
and reduced C3/C4 levels (73/6 mg/dL). ADAMST-13 activity 
was normal, and no antibodies directed against ADAMST-13 
were encountered. She had no history of diarrhea, and stool 
cultures for bacteria were negative. A diagnosis of aHUS was 
suspected, and plasma exchange was immediately started and 
then continued on a daily basis, with improvement in hema-
tological parameters. Since worsening kidney function (serum 
creatinine reached 2.37 mg/dL for eGFR 27 mL/minutes esti-
mated with CKD-EPI equation) and proteinuria were observed, 
a kidney biopsy was performed; histological analysis showed 
a picture of TMA. After 22 PEX sessions and completion of ap-
propriate vaccination schedule, the patient was started on in-
travenous Eculizumab (600 mg every week for 1 month, then 
900 mg every 2 weeks). Dramatic clinical improvement was 
observed: platelet count normalized, signs of hemolysis grad-
ually disappeared (normal serum LDH and haptoglobin levels) 
and kidney function recovered. Genetic analysis was performed 
with Next Generation Sequencing. No mutations predispos-
ing to aHUS were encountered in CFH (complement factor H), 
MCP (membrane cofactor protein), CFI (complement factor I), 
C3, CFB (complement factor B), and THBD (thrombomodulin) 
genes. Nevertheless, she was determined to be a carrier of 2 
polymorphisms in CFH and one in MCP genes, which are more 
frequently observed in aHUS patients.
The patient was maintained on 900 mg Eculizumab infusion 
every 2 weeks. Her clinical picture remained stable with no 
signs of hemolysis, normal platelet count, only moderate com-
plement consumption, mild kidney dysfunction with chronic 
kidney disease (CKD) stage II (eGFR 60–75 mL/minutes esti-
mated with CKD-EPI equation), and proteinuria/creatininuria 
around 0.5. Arterial hypertension was successfully treated with 
a combination of drugs including a renin inhibitor.
At 42 months from the initiation of Eculizumab, the patient 
became pregnant. As depicted in Figure 1, her serum creati-
nine decreased to a nadir of 0.8 mg/dL at 20 weeks of gesta-
tion, and then stabilized at 1.1 mg/dL; her proteinuria/creat-
ininuria levels increased up to 2; her serum complement levels 
remained substantially stable, and there were no signs of in-
travascular hemolysis (normal platelet count, lactate dehydro-
genase levels, haptoglobin levels). She developed worsening 
hypertension despite multiple drugs combination treatment 
starting from 26 weeks of gestation, and therapy was adjusted; 
from the 20th week, she complained about peripheral edema. 
A diagnosis of pre-eclampsia superimposed on chronic pre-ex-
isting hypertension and CKD was made. Since no features of 
severe pre-eclampsia were present, a conservative manage-
ment was attempted. Fetal weight and length were appropri-
ate for gestational age, with no evident organ abnormalities 
on ultrasound. Starting from 26 weeks of gestation, a decrease 
in serum haptoglobin was detected at the laboratory exami-
nations. At the end of the 26th week of gestation, she noted 
worsening of peripheral edema and urine output reduction 
and was admitted to the obstetric ward. Blood pressure was 
140/100 mmHg. Laboratory tests showed acute kidney injury 
(AKI) stage II according to AKI classification [10] (serum creat-
inine 1.67 mg/dL), anemia, high serum LDH, and low platelet. 
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Figure 1.  Trends of serum creatinine (A, dark-grey line), proteinuria/creatininuria (A, light grey line), platelets (B, dashed black 
line), hemoglobin (A, continuous black line), serum C3 (C, dark-grey line), serum C4 (C, light-grey line), and serum lactate 
dehydrogenase (C, dashed black line) during pregnancy. PLT – platelets; Hb – hemoglobin; LDH – lactate dehydrogenase.
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Eculizumab was administered at the dose of 1200 mg; induc-
tion of fetal pulmonary maturation was started. On day 27 
weeks+0, after a PEX session, a cesarean section was per-
formed and the patient delivered a low birth weight prema-
ture male baby (weight 827 grams) normal for gestational age, 
who was immediately transferred to the intensive care unit. 
The patient developed worsening AKI (zenith serum creatinine 
2.7 mg/dL). She maintained reduced serum C3 and C4 levels, 
and low serum haptoglobin. In the following days, the patient 
was treated with 8 PEX sessions and administration of supple-
mental Eculizumab after every session, as reported in Figure 1. 
The clinical picture started to improve with resolution of the 
hemolysis and slow improvement of renal function. After dis-
charge, treatment was continued with weekly Eculizumab in-
fusion at the dose of 900 mg. At 1 month from delivery, the 
patient is doing well, her serum creatinine was 1.6 mg/dL for 
an eGFR of 42 mL/minute (CKD-EPI), proteinuria/creatininuria 
was 0.66, serum C3/C4 were 81/18 mg/dL, hemoglobin was 
11.1 g/dL, platelets and haptoglobin were normal. The baby 
had a prolonged stay in the intensive care unit. He showed 
no signs of neurologic damage and he was included in a spe-
cific follow-up program.
Discussion
Pregnancy in patients with aHUS represents a challenge to 
the clinician, given the high risk of TMA reactivation and other 
complications. Current consensus states that each pregnancy 
should be considered individually and carefully planned [11]. 
Indeed, overall knowledge on the ideal care in these patients 
is scarce. Pregnancy always represents a potential trigger for 
TMA relapse in women with aHUS, as per se elicits comple-
ment activation. Complement mediated immune attack can oc-
cur at the placental level with the potential risk of fetal dam-
age. Moreover, during delivery, inflammation, release of fetal 
cells, infections, and hemorrhage can lead to systemic activa-
tion of the alternative complement pathway [12].
Eculizumab has been used in pregnant patients with PNH, 
with excellent results [9]. Preliminary data from PNH patients 
suggest that its use might be safe, at least in the short term, 
for the fetus [13].
We searched PubMed database for English language reports 
from inception until February 2018 using the following search 
terms: “Eculizumab” AND “hemolytic uremic syndrome” AND 
“pregnancy”.
Literature data about the positive use of Eculizumab for 
the treatment of pregnancy-associated aHUS appear quite 
solid [14]. Furthermore, Ardissino et al. [7] reported a case 
of a 26-year-old woman with aHUS due to a homozygous 
mutation in CFH, previously treated with PEX, who developed 
a relapse of aHUS at 17 weeks of gestation. She was treat-
ed with Eculizumab from 26 weeks of gestation and eventu-
ally gave birth to a healthy female baby by cesarean section.
There is scarce available data about pregnancy in women pre-
viously diagnosed with aHUS and on maintenance treatment 
with Eculizumab. Servais et al. [8] reported 5 pregnancies in 3 
patients with aHUS with ongoing Eculizumab treatment. All 3 
patients had a mutation in complement genes responsible for 
aHUS (1 heterozygous CFH mutation, 1 heterozygous C3 muta-
tion, and 1 heterozygous CFI mutation plus a rare C3 variant). 
For all 3 patients, births occurred by cesarean section between 
29 and 34 weeks of gestation. The authors reported 1 in ute-
ro death and 2 cases of fetal growth retardation. In addition, 
2 neonates had prolonged hospital stay. Of note, the only fe-
tal death occurred in a pregnancy where the mother had ad-
vanced CKD (stage IV, eGFR 28 mL/minute). Described mater-
nal complications included 1 case of HELLP syndrome and 2 
cases of pre-eclampsia; no relapses of aHUS were reported in 
the post-partum period. The authors reported to have increased 
Eculizumab dose in all pregnancies in response to incomplete 
C5 inhibition (estimated by measurement of complement ac-
tivity enzyme) or elevation of CH50. Although Eculizumab 
might cross the placenta, its levels should not be high enough 
to block complement cascade. Eculizumab was not detected 
in umbilical cords or neonate plasma samples in 2 of the pa-
tients described in their study [8]. Recently, a successful preg-
nancy in a kidney transplantation patient who was receiving 
maintenance Eculizumab for aHUS has been reported [15]. In 
that case, moderate pre-eclampsia and fetal growth faltering 
were present from week 28 of gestation, and a cesarean de-
livery was scheduled at week 32 of gestation.
Our patient had a spontaneous pregnancy during maintenance 
Eculizumab treatment with normal fetal development, com-
plicated by pre-eclampsia by week 20 of gestation and aHUS 
relapse at week 26 of gestation. A form of pre-eclampsia with 
severe features and HELLP syndrome were considered the dif-
ferential diagnosis [16,17]; nevertheless, the previous histo-
ry of aHUS and the absence of elevation of ALT/AST enzymes 
oriented the diagnosis towards an aHUS relapse. She had sev-
eral risk factors for the development of pre-eclampsia, namely 
pre-existing hypertension [18] and chronic kidney disease [19]. 
Given the lack of signs of TMA, she was initially maintained 
throughout the first 26 weeks of pregnancy with her usual 
Eculizumab dose (900 mg intravenously every 2 weeks). After 
detection of TMA reactivation, she was treated with supple-
mental Eculizumab, PEX, and immediate cesarean delivery.
Unfortunately, we could not measure complement activi-
ty or Eculizumab blood levels in our patient. Nevertheless, 
although CH50 activity has been directly related to intravascular 
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hemolysis and circulating free Eculizumab levels in patients 
with PNH [20], there is no definitive prove that its measure-
ment can predict a relapse of aHUS [21,22], and its levels has 
been reported to be not reliable to tailor Eculizumab optimi-
zation [23]. Furthermore, CH50 levels gradually increase dur-
ing pregnancy from 10% to 50%, complicating its correct inter-
pretation in this context [12,24]. It is possible that our patient 
had inadequate complement blockage due to altered pharma-
cokinetics of Eculizumab during pregnancy, related to modi-
fications in total plasma volume, plasma protein, and organ 
blood flow. We believe that, based on our negative experience, 
therapeutic drug monitoring of Eculizumab will be fundamen-
tal in future similar cases in order to ensure adequate main-
tenance treatment [25].
Cumulative available data on pregnancy during Eculizumab 
treatment in aHUS are summarized in Table 1. Median time 
from start of Eculizumab treatment to pregnancy according to 
available reports was 18 months.
Eculizumab treatment apparently prevents relapse of aHUS dur-
ing and immediately after pregnancy in women with known com-
plement-regulating genes mutations, even though current knowl-
edge is based only on isolated case reports. Possibly, an increase 
in the maintenance dose of Eculizumab during pregnancy and 
immediately after delivery could be warranted, although data 
robust enough to define a clear recommendation are lacking.
On the other hand, we report the first case of aHUS relapse in 
a pregnant woman in maintenance treatment with Eculizumab. 
It should be noted that the patient had no pathogenic mutation 
for aHUS in complement-regulating genes. It is widely known 
that aHUS can be explained by the presence of specific muta-
tions in complement genes only in 40–60% of cases [6], and 
Eculizumab treatment is generally used with proved efficacy 
in patients with a diagnosis of aHUS with no specific gene mu-
tation [2]. Given the rarity of the condition itself, the paucity 
of data about pregnancy in these patients and the difficulty 
in performing clinical trials in this setting, we believe that it is 
important to report the association of aHUS without specific 
gene mutation and pregnancy-associated relapse of TMA de-
spite maintenance Eculizumab administration.
Women with aHUS in maintenance treatment with Eculizumab 
present a high risk for eclampsia and HELLP syndrome. In the 
absence of clear signs of ongoing TMA, mechanisms leading to 
pre-eclampsia and its related syndrome are possibly unconnect-
ed to complement activation and might be secondary to pre-ex-
isting CKD. Indeed, women with kidney dysfunction are known 
to be at higher risk for pre-eclampsia, eclampsia, and HELLP [19]. 
Pregnancies in women with aHUS treated with Eculizumab 
appear to be at risk for fetal growth restriction and intrauter-
ine death. These complications could be attributed to pre-ex-
isting kidney dysfunction, as the association between intra-
uterine growth retardation, poor fetal outcome and maternal 
CKD is well known [19].
There is no information available about long-term effects of 
maternal Eculizumab administration during pregnancy in ne-
onates and infants; nevertheless, high rates of fetal survival 
have been reported in pregnancies in patients with PNH treat-
ed with Eculizumab [9]. Reassuringly, Eculizumab treatment 
during pregnancy has been reported to not impair the com-
plement function in the newborn [26].
Pregnancy Author Age (years)
Time from 
Eculizumab 
start and 
pregnancy 
(months)
s-Creatinine 
[mg/dL], 
(eGFR [mL/
min]) before 
pregnancy
s-Creatinine 
[mg/dl] 
during 
pregnancy 
pr/cr 
during 
pregnancy
s-Creatinine 
[mg/dL] at 
delivery
pr/cr at 
delivery
Fetal (neonatal) 
complications
Birth 
weight 
(g)
Maternal 
complications
1 Servais 
et al. [8]
31 6 1.9 (32) 1.5 N.a. 1.9 1.5 (Prolonged 
hospital stay)
1550 HELLP syndrome
2 Servais 
et al. [8]
33 18 1.6 (40) 1.3 N.a. 1.3 0.8 2500
3 Servais 
et al. [8]
29 12 1.5 (45) 1.4 N.a. 2.7 6.8 Growth 
retardation 
(prolonged 
hospital stay)
1410
4 Servais 
et al. [8]
26 12 2.3 (28) n.a. N.a. In utero death Pre-eclampsia
5 Servais 
et al. [8]
27 17 2.2 (29) 1.8 N.a. 1.9 1.3 Growth 
retardation
1070 Pre-eclampsia
6 Fontana 
et al.
31 42 1.2 (60) 0.89 (86) 1.9 1.78 2.8 (Prolonged 
hospital stay)
827 Pre-eclampsia, 
aHUS relapse
Table 1. Data from 6 pregnancies during eculizumab treatment in women with aHUS.
pr/cr – proteinuria/creatininuria. Fetal growth retardation defined as fetal size below 10th percentile.
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Conclusions
In summary, we report the case of pregnancy-associated aHUS 
relapse in a patient undergoing maintenance Eculizumab treat-
ment. Previous reports of 3 women with aHUS with known com-
plement-regulating genes mutations described no episodes of 
TMA during pregnancy under maintenance Eculizumab treat-
ment. Our patient had no pathogenic mutations in complement-
regulating genes. Clinicians should be aware of possible aHUS 
relapse in pregnancy during Eculizumab treatment. Monitoring 
of Eculizumab blood levels and complement activity (CH50) 
is desirable to guide clinical decisions [25]. However, optimal 
biomarker for Eculizumab treatment monitor is currently un-
known. Also, the lack of evidence of the optimal Eculizumab 
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